Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the year ended December 31, 2013. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares after opening at $1.10 moved to $1.14 on last trade day and at the end of the day closed at $1.01.Company price to cash ratio as 11.89. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) showed a negative weekly performance of -14.41%.
Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the May 5, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma, Inc. (Nasdaq:GALE) between May 9, 2013 and March 17, 2014, inclusive (the “Class Period”). Galena Biopharma Inc (NASDAQ:GALE) shares fell -8.74% in last trading session and ended the day on $1.88. GALE return on equity ratio is recorded as -435.40% and its return on assets is -113.60%. Galena Biopharma Inc (NASDAQ:GALE) yearly performance is -13.76%.
Cel-Sci Corporation (NYSEMKT:CVM) saw its stock plunge after pricing a public offering of over 7 million shares of stock.Pricing the units at $1.40 apiece for gross proceeds of $10 million. Each unit includes a share of common stock and a $0.25 warrant, exercisable immediately with an expiration date of October 17, 2014, for purchase of another share of common stock at a price of $1.58 apiece. CEL-SCI Corporation (NYSEMKT:CVM) shares moved down -13.24% in last trading session and was closed at $1.31, while trading in range of $1.27-$1.41. CEL-SCI Corporation (NYSEMKT:CVM) year to date performance is 122.03%.
Zacks upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from an underperform rating to a neutral rating in a research note released on Wednesday morning, AnalystRatingsNetwork.com reports. They currently have $2.10 target price on the stock. Amicus Therapeutics, Inc. (NASDAQ:FOLD) weekly performance is -5.66%. On last trading day company shares ended up $2.00. Amicus Therapeutics, Inc. (NASDAQ:FOLD) distance from 50-day simple moving average is -16.26%. Analysts mean target price for the company is $3.83.
Leave a Reply